Source: PatientView
An new independent study by PatientView ‘The Corporate Reputation of
Pharma in 2014 – the Patient Perspective’, sets out the the corporate
reputation of pharma companies from a patient perspective, and details what has
changed over the past four years. In summary:
- Findings based on a survey of 1,150 patient groups (from 58 countries and of differing specialties)
- Survey conducted mid-November 2014 to mid-January 2015
- Patient-group feedback on the corporate reputation of the entire pharma industry during 2014
- Patient-group feedback on the corporate reputation of 37 individual pharma companies in 2014
- Results for 2014 are compared with those of 2013, 2012, and 2011
The 37 pharma companies reviewed in the study are: AbbVie l Actavis l
Allergan l Amgen l Astellas l AstraZeneca l Baxter International l Bayer l
Biogen Idec l Boehringer-Ingelheim l Bristol-Myers Squibb l Celgene l Eisai l
Eli Lilly (Lilly) l Gilead l GlaxoSmithKline (GSK) l Grũnenthal l Ipsen l
Janssen l Lundbeck l Menarini l Merck & Co (USA) l Merck KgA (Germany) l
Mylan l Novartis l Novo Nordisk l Otsuka l Pfizer l Roche l Sanofi l Servier l
Shire l Stada Arzneimittel l Takeda l Teva l UCB l ViiV Healthcare
Results for individual pharma companies
The corporate reputation of individual pharma companies (as seen from a
patient perspective) shows some significant changes between 2014 and 2013 (37
companies assessed in 2014; 33 companies in 2013).